Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity

Cynthia D. Jesudason,* James E. Baker, Robert D. Bryant, Jack W. Fisher, Libbey S. O'Farrell, Gregory A. Gaich, Minxia M. He, Steven D. Kahl, Aidas V. Kriauciunas, Mark L. Heiman, Mary A. Peters, Christopher J. Rito, Julie H. Satterwhite, Frank C. Tinsley, William G. Trankle, and Anthony J. Shuker⁺

Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States

Supporting Information

ABSTRACT: We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide (LY377604), a human β_3 adrenergic receptor agonist and β_1 - and β_2 -adrenergic receptor antagonist with no sympathomi-



metic activity at the β_{1-} and β_{2-} adrenergic receptors, is reported. Some in vivo data in both rats and humans is presented.

KEYWORDS: Selective beta adrenoceptor modulator, β_3 -adrenergic receptor agonist, norepinephrine-serotonin uptake inhibitor, sibutramine, LY377604, obesity

besity has increasingly been cited as a major health issue in recent decades.¹ While many industrialized countries have experienced similar increases, obesity rates in the United States are among the highest in the world, with thirty-three states having a prevalence equal to or greater than 25% and nine of these have a prevalence equal to or greater than 30% in 2009.²

Three drugs have been marketed for the long-term treatment of obesity: orlistat, which inhibits pancreatic lipase and consequently fat digestion; sibutramine, which acts centrally to inhibit norepinephrine and serotonin reuptake; and rimonabant, which antagonizes the cannabinoid receptor-1 in both the brain and peripheral tissues. Rimonabant and sibutramine have recently been withdrawn, owing to concerns about psychiatric side effects and cardiovascular safety concerns, respectively. Orlistat has had modest sales, in part because of its side effects and limited efficacy.

The discovery of a third β -adrenergic receptor in the early 1980s and the finding that stimulation of this receptor by selective agonists leads to marked weight loss and glycemic improvements in rodent models of obesity and diabetes, respectively, have led to intensive research efforts to develop β_3 adrenergic agonists for the treatment of obesity and Type 2 diabetes in humans.^{3–5} Activation of the β_3 -adrenergic receptor markedly increases thermogenesis in rodents, and in fat tissue it stimulates oxidation of free fatty acids and lipolysis.^{6,7} Early clinical studies on BRL 35135 and BRL 26830A (1 and 2, Figure 1) support the potential antihyperglycemic and antiobesity effects of β_3 -adrenergic receptor agonists in humans.^{8–10} The role of brown adipose tissue (BAT) metabolism in humans is still debated, and there is disagreement, for example, on the amount of BAT that is present in adults.¹¹ It is clear, however, that, within brown adipocytes, significant levels of uncoupling protein mRNA have been detected, along with β_3 -receptor



Figure 1. Selected β_3 adrenergic receptor agonists reported in the literature.

mRNA.¹² Furthermore, the effects of β_3 -receptor stimulation within BAT have been demonstrated in human subjects or tissues isolated from humans using the nonselective β -receptor agonist isoproterenol in the presence of β_1 - and β_2 -adrenergic receptor blockade or by more selective "atypical" partial β_3 -receptor agonists, such as CGP 12177 (3, Figure 1).^{13–15} In addition, treatment with β_3 -receptor agonists results in differentiation of preadipocytes to BAT in both rats and humans.¹⁶ These data suggest that the amount and the metabolic activity of BAT may be increased with chronic β_3 -receptor agonist therapy.^{17,18} Clinical studies with our human β_3 -adrenergic receptor agonist LY377604

Received:	March 14, 2011
Accepted:	May 23, 2011
Published:	May 23, 2011

(4) have shown an increase in energy expenditure in healthy male subjects, ¹⁹ and this is further corroborated by single dose data from L-796,568 (5) in obese subjects.^{20,21}

One dose-related side effect of sibutramine (6, Figure 2) treatment is an increase in blood pressure and heart rate due to activation of the sympathetic nervous system. We postulated that dosing in combination with LY377604 would ameliorate this by taking advantage of the β_1 and β_2 blocking properties of this compound, in addition to perhaps giving a synergistic increase in body weight loss in humans.

The synthesis of LY377604 (4) is outlined in Scheme 1.²² A mixture of 4-hydroxybenzyl alcohol (7) and 2-nitropropane was heated with potassium *tert*-butoxide using a Dean–Stark trap to provide 4-(2-methyl-2-nitropropyl)phenol (8), which was hydrogenated to yield the corresponding amine (9). The next step in the synthesis involved a based-promoted S_NAr , whereby 4-(2-methyl-2-aminopropyl)phenol (9) was treated with powdered potassium carbonate and 6-chloronicotinamide to provide the coupled product (10) in 86% yield. In the final step, (*S*)-4-(oxiranylmethoxy)-9H-carbazole²³ is treated with 2 equiv of the amine (10) to provide LY377604 (4) as a free base which is subsequently converted to the HCl salt or hemisuccinate.²⁴

LY377604 was initially examined for its ability to stimulate the human β_3 adrenergic receptor expressed in Chinese hamster



Figure 2. Structure of sibutramine.

Scheme 1^{*a*}

ovary (CHO) cells. The compound was tested and found to be a potent agonist (EC₅₀ = 2.4 nM, n = 14) and to cause a maximal increase in cyclic adenosine monophosphate (cAMP) levels that was approximately 74% of the maximal response induced by isoproterenol. LY377604 did not stimulate cAMP accumulation in CHO cells transfected with either the human β_1 adrenergic receptor or the human β_2 adrenergic receptor. Interestingly, this lack of efficacy to stimulate cAMP production was not a result of poor binding to the human β_1 and β_2 adrenergic receptors. LY377604 bound with high affinity to membranes expressing the human β_1 adrenergic receptor and the human β_2 adrenergic receptor. The in vitro data for LY377604 is summarized in Table 1.



Figure 3. LY377604 decreases the respiratory quotient in diet-induced obese male Long–Evans rats for 4 h at both 3 and 10 mg/kg orally (p < 0.05 ANOVA, SNK). The respiratory quotient was measured by indirect calorimetry.



^{*a*} Reagents and conditions: (a) 2-nitropropane, KOtBu, diglyme, 132 °C; (b) 5% Pd/C, H₂, 50 psi, HOAc, MeOH/EtOH, 50 °C; (c) 6-chloronicotinamide, K₂CO₃, DMAC/iso-octane 140 °C; (d) (*S*)-4-(oxiranylmethoxy)-9H-carbazole, MeOH, 60 °C; (e) HCl, EtOAc; (f) succinic acid (0.5 equiv), EtOH.

Table 1. Beta Adrenergic B	nding and Functiona	l Activities of LY377604 ·	HCl or LY3770	604 · Hemisuccinate"
----------------------------	---------------------	----------------------------	---------------	----------------------

human β_3 functionalrat β_3 functionalcAMP accumulationcAMP accumulation		unctional cumulation	human eta_2 functional cAMP accumulation		human eta_1 functional cAMP accumulation		human eta_2 radioligan binding	d human eta_1 radioligand binding	
EC_{50} (nM)	E_{\max} (%)	EC_{50} (nM)	E_{\max} (%)	EC_{50} (nM)	E_{\max} (%)	EC_{50} (nM)	E_{\max} (%)	$K_{\rm i} ({\rm nM})^b$	$K_{\rm i} ({\rm nM})^b$
2.4 ± 0.2	73.8 ± 1.0	5.0 ± 1.2	55.5 ± 2.0	>3160	<10	>3160	<10	0.012 ± 0.002	0.023 ± 0.005
(n = 14)	(n = 14)	(n = 12)	(n = 12)	(n = 4)	(n = 4)	(n = 4)	(n = 4)	(n = 4)	(n = 4)
^a Standard d	eviations are	indicated	by \pm of	the geometric	mean, a	nd the num	ber of runs	is indicated by	(<i>n</i>). ^{<i>b</i>} Data obtained on

LY377604 · hemisuccinate.



Figure 4. LY377604 increases caloric expenditure in diet-induced obese male Long-Evans rats for 4 h at 10 mg/kg orally (p < 0.05 ANOVA, SNK). Energy expenditure was measured by indirect calorimetry.



Figure 5. LY377604 blocks the sibutramine-induced increase in heart rate produced by a 30 mg dose of sibutramine at all dose levels in healthy volunteers.

Administration of LY377604 to male Long-Evans rats fed a caloric dense diet resulted in stimulation of lipid utilization. This was observed as a decrease in respiratory quotient and persisted for about 4 h before returning to that measured from vehicletreated rats (Figure 3).²⁵ The increase in lipid utilization was dependent on dose. This was accompanied by a concomitant dose-dependent increase in energy expenditure (Figure 4). The increased fuel consumption was also maintained for about 4 h. We have previously reported the clinical confirmation of this increase in energy expenditure and reduction in respiratory quotient in a placebo controlled phase I dose escalation study of LY377604.¹⁹ Single doses of LY377604 also resulted in the expected β_2 adrenergic antagonist activity as assessed by venous tonometry during localized isoproterenol administration in a dorsal hand vein.

In healthy volunteers, LY377604 was rapidly absorbed, with maximum plasma concentrations achieved at approximately 2 h. LY377604 showed a rapid initial decline from plasma, followed by a slower terminal elimination phase; the estimated half-life was 9 h after a 60-mg dose.

In preparation for a phase II obesity study of LY377604 in combination with sibutramine, it was determined that LY377604 did not alter the pharmacokinetics of sibutramine or its active metabolites over the dosing range studied (45-300 mg) in human volunteers. All dose levels of LY377604 blocked the cardiovascular effects of a 30 mg dose of sibutramine to a similar extent and demonstrated net decreases from baseline for heart rate (-10.5 bpm, Figure 5), systolic blood pressure (-5.5 mmHg), and diastolic blood pressure (-4.2 mmHg). Results from the phase II obesity study for this combination will be reported in due course.

ASSOCIATED CONTENT

S Supporting Information. Synthetic procedures and characterization data for all compounds, protocols for the human β adrenergic functional and binding assays, and DIO rat obesity studies. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Telephone: 317-276-7984. Fax: 317-277-7287. E-mail: jesudason cynthia d@lilly.com.

Notes

[†]In memoriam of Anthony J. Shuker, who passed away on March 26, 2009.

ACKNOWLEDGMENT

We thank Robert D. Boyer, Lawrence A. Goodwin, and Douglas F. Schmidt for analytical support, Don Bennett for assay support, and Marlene L. Cohen for advice and mentorship.

ABBREVIATIONS

 β_1 , beta 1; β_2 , beta 2; β_3 , beta 2;LY377604, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carboxamide; cAMP, cyclic adenosine monophosphate; ANOVA, analysis of variance; SNK, Student-Newman-Keuls

REFERENCES

(1) Kelly, T.; Wang, W.; Chen, C.-S.; Reynolds, K.; He, J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obes. 2008, 32, 1431-1437. (2) http://www.cdc.gov/obesity/data/trends.html.

(3) de Souza, C. J.; Burkey, B. F. Beta 3-Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans. Curr. Pharm. Des. 2001, 7, 1433-1449.

(4) Weyer, C.; de Souza, C. J. Development of β_3 -Adrenoceptor Agonists as Antiobesity and Antidiabetes Drugs in Humans: Current Status and Future Prospects. Drug Dev. Res. 2000, 51, 80-93.

(5) Arch, J. R. S. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β_3 adrenoceptor agonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 2008, 378, 225-240.

(6) Arch, J. R. S.; Ainsworth, A. T.; Cawthorne, M. A.; Piercy, V.; Sennitt, M. V.; Thody, V. E.; Wilson, C.; Wilson, S. Atypical β -adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984, 309, 163-165.

(7) Arch, J. R. S.; Ainsworth, A, T.; Ellis, R. D. M.; Piercy, V.; Thody, V. E.; Thurlby, P. L.; Wilson, C.; Wilson, S.; Young, P. Treatment of obesity with thermogenic β -adrenoceptor agonists: studies on BRL 26830A in rodents. *Int. J. Obes.* **1984**, *8* (Suppl 1), 1–11.

(8) Connacher, A. A.; Bennet, W. M.; Jung, R. T.; Rennie, M. J. Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A. *Int. J. Obes. Relat. Metab. Disord.* **1992**, *16*, 685–694.

(9) Mitchell, T. H.; Ellis, R. D.; Smith, S. A.; Robb, G.; Cawthorne, M. A. Effects of BRL 35135, a beta-adrenoceptor agonist with novel selectivity, on glucose tolerance and insulin sensitivity in obese subjects. *Int. J. Obes.* **1989**, *13*, 757–766.

(10) Cawthorne, M. A.; Sennitt, M. V.; Arch, J. R.; Smith, S. A. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist. *Am. J. Clin. Nutr.* **1992**, *55* (1 Suppl), 2528–257.

(11) Nedergaard, J.; Bengtsson, T.; Cannon, B. Unexpected evidence for active brown adipose tissue in adult humans. *Am. J. Physiol. Endocrinol. Metab.* **2007**, 293, E444–E452.

(12) Champigny, O.; Ricquier, D. Evidence from in vitro differentiating cells that adrenoceptor agonists can increase uncoupling protein mRNA level in adipocytes of adult humans: an RT-PCR study. *J. Lipid Res.* **1996**, *37*, 1907–1914.

(13) Lonnqvist, F.; Krief, S.; Strosberg, A. D.; Nyberg, S.; Emorine, L. J.; Arner, P. Evidence for a functional beta 3-adrenoceptor in man. *Br. J. Pharmacol.* **1993**, *110*, 929–936.

(14) Wheeldon, N. M.; McDevitt, D. G.; Lipworth, B. J. Do beta 3-adrenoceptors mediate metabolic responses to isoprenaline? *Q. J. Med.* **1993**, *86*, 595–600.

(15) Enocksson, S.; Shimizu, M.; Lonnqvist, F.; Nordenstrom, J.; Arner, P. Demonstration of an in vivo functional beta 3-adrenoceptor in man. J. Clin. Invest. **1995**, *95*, 2239–2245.

(16) Himms-Hagen, J.; Ricquier, D. Brown adipose tissue. In *Handbook of obesity*; Bray, G. A., Bouchard, C., James, W. P. T., Eds.; Marcel Dekker: New York, pp 415–441.

(17) Holloway, B. R. Reactivation of brown adipose tissue. Proc. Nutr. Soc. 1989, 48, 225–230.

(18) Kawashita, N. H.; Moura, M. A.; Brito, M. N.; Brito, S. M.; Garofalo, M. A.; Kettelhut, I. C.; Migliorini, R. H. Relative importance of sympathetic outflow and insulin in the reactivation of brown adipose tissue lipogenesis in rats adapted to a high-protein diet. *Metabolism* **2002**, *51*, 343–349.

(19) Miller, J. W.; Farid, N. A.; Johnson, R. D.; Smith, B. P.; Dananberg, J. Stimulation of energy expenditure by LY377604, a β_3 adrenergic receptor agonist with $\beta_{1/2}$ antagonist properties in healthy male subjects. *Obes. Res.* **1999**, 7 (Suppl. 1), 121S.

(20) van Baak, M. A.; Hul, G. B. J.; Toubro, S.; Astrup, A.; Gottesdiener, K. M.; DeSmet, M.; Saris, W. H. M. Acute effect of L-796568, a novel β_3 -adrenergic receptor agonist, on energy expenditure in obese men. *Clin. Pharmacol. Ther.* **2002**, *71*, 272–279.

(21) Larsen, T. M.; Toubro, S.; van Baak, M. A.; Gottesdiener, K. M.; Larson, P.; Saris, W. H.; Astrup, A. Effect of a 28-d treatment with L-796568, a novel β_3 -adrenergic receptor agonist, on energy expenditure and body composition in obese men. *Am. J. Clin. Nutr.* **2002**, *76*, 780–8.

(22) Czeskis, B. A.; Wheeler, W. J.; Clodfelter, D. K. Convergent synthesis of two 14C-labeled β_3 -adrenergic receptor agonists. *J. Labelled Compd. Radiopharm.* **2006**, *49*, 663–673.

(23) Czeskis, B. A.; Wheeler, W. J. Synthesis of β_3 adrenergic receptor agonist LY377604 and its metabolite 4-hydroxycarbazole, labeled with carbon-14 and deuterium. *J. Labelled Compd. Radiopharm.* **2005**, 48, 407–419.

(24) Crowell, T. A.; Evrard, D. A.; Jones, C. D.; Muehl, B. S.; Rito C. J.; Shuker, A. J.; Thorpe, A. J.; Thrasher, K. J.; Czeskis, B. A.; Wheeler, W. J. EP Patent 0 827 746, 2002.

(25) Procedure based on method reported in: Chen, Y.; Heiman, M. L. Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. *Regul. Pept.* **2000**, *92*, 113–119.